Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Krystal Biotech Q3 2026 Results: Net Income $63.1M, Down 20.5% YoY

Krystal Biotech reported a strong third quarter in 2026, with product revenue increasing to $127.3 million compared to $97.8 million in the prior year. Net income for the nine months ended September 30, 2026, rose to $173.8 million, supported by significant growth in cash and investments totaling over $1.19 billion.

Watch the Krystal Biotech, Inc. earnings callFull call on the ALFA USA YouTube channel
Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue127.397.8
Profit before tax80.148.0
Net income63.179.4
EPS (diluted, $ a share)$2.05$2.66

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year-20.5%
Revenue, year on year+30.2%
Operating margin55.9%
Source

10-Q filed with the SEC, NASDAQ: KRYS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Krystal Biotech, Inc.: key numbers

Share price
$297.90Close, Nov 16
Market cap
$8.83B
Shares outstanding
29.63MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Krystal Biotech, Inc.

All →
7:07 AM ET 8-K
Financial Results

Krystal Biotech Financial Results

Krystal Biotech reported third quarter 2026 financial results, highlighted by $127.3 million in global VYJUVEK net product revenue, a 30% year-over-year increase. The company ended the quarter with a strong cash position of $1.2 billion and announced a new $400 million share repurchase program. Additionally, the company completed pricing negotiations for VYJUVEK in Germany and Italy and reported positive clinical data for its KB113 candidate in Gorlin syndrome.

“Continued growth in VYJUVEK revenue is supporting profitability and funding the advancement of our pipeline. Our financial strength allows us to invest fully in these programs and our global commercial expansion while returning capital to shareholders. The $400 million share repurchase program, under which we expect to repurchase shares opportunistically over the next two years, reflects our confidence in Krystal’s long-term growth prospects and our commitment to disciplined capital allocation.”

Krish S. Krishnan, Chairman and Chief Executive Officer
7:02 AM ET 8-K
Clinical Trial Data

Krystal Biotech Clinical Trial Data

Krystal Biotech announced positive proof-of-concept clinical data from its Gorlin Syndrome Pilot Study evaluating KB113 for the treatment of basal cell carcinomas. The study showed that over 80% of assessed lesions regressed across three patients, including non-injected lesions, suggesting a systemic abscopal effect.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.